Profound Medical (TSE:PRN) Hits New 1-Year High – Time to Buy?

Profound Medical Corp. (TSE:PRN)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as C$12.40 and last traded at C$11.85, with a volume of 11025 shares traded. The stock had previously closed at C$12.11.

Profound Medical Stock Performance

The company has a debt-to-equity ratio of 20.05, a quick ratio of 14.98 and a current ratio of 6.12. The company has a market capitalization of C$421.00 million, a P/E ratio of -8.79 and a beta of 1.19. The business has a 50 day moving average of C$9.67 and a 200-day moving average of C$8.15.

Profound Medical (TSE:PRN) last issued its earnings results on Thursday, November 13th. The company reported C$0.26 EPS for the quarter. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%.The business had revenue of C$7.36 million during the quarter. On average, sell-side analysts predict that Profound Medical Corp. will post -1.9000001 EPS for the current fiscal year.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.